Scribe Therapeutics

We are a biotechnology research company creating genetic medicines using our CRISPR by Design™ approach. We engineer CRISPR-based therapeutics to be safe and effective, helping to reduce individuals’ risk for disease over their lifetime.

Our approach involves comprehensive molecular engineering, developing CRISPR systems with small, deliberate steps to ensure they are safe and specific for many applications. Our therapeutic work initially focuses on cardiometabolic disease. We expect to begin clinical trials in mid-2026 with STX-1150, a PCSK9-targeting CRISPR epigenetic silencing therapy designed to lower LDL-C.

We collaborate with partners such as Sanofi on ex vivo NK cell therapies in oncology and in vivo therapies for sickle cell and other genomic diseases, and Lilly for neurological and neuromuscular diseases.

Scribe Therapeutics was founded by CRISPR researchers from UC Berkeley, including Jennifer A. Doudna, PhD, Benjamin L. Oakes, PhD, David F. Savage, PhD, and Brett T. Staahl, PhD. We are located at 1150 Marina Village Pkwy, Alameda, CA 94501.

We are committed to making CRISPR-based therapeutics safe and effective, aiming to reshape how individuals manage their health risks throughout their lives. Our vision is to empower a world where people control their health destinies.

We are dedicated to ensuring CRISPR is safe and effective for broad use. Our work follows a principle of comprehensive molecular engineering: we take small, deliberate steps. We believe CRISPR medicine should not take shortcuts, and this approach helps us maximize human health through safe and effective genetic medicines.

We are a biotechnology research company with 51 to 200 employees. We look for individuals who are driven, creative, pragmatic, and demonstrate integrity.